Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
BACKGROUND: The amyloid-beta peptide Abeta(42) has been implicated in the pathogenesis of Alzheimer's disease (AD). We aimed to test the effects of tarenflurbil, a selective Abeta(42)-lowering agent (SALA), on cognition and function in patients with mild to moderate AD. METHODS: 210 patients li...
| Main Authors: | , , , , , |
|---|---|
| Formato: | Journal article |
| Idioma: | English |
| Publicado: |
2008
|